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Inherited amino acid substitutions at position 21, 22,
or 23 of amyloid  (A) lead to presenile dementia or
stroke. Insulin-degrading enzyme (IDE) can hydrolyze
A wild type, yet whether IDE is capable of degrading
A bearing pathogenic substitutions is not known. We
studied the degradation of all of the published A ge-
netic variants by recombinant rat IDE (rIDE). Mono-
meric A wild type, Flemish (A21G), Italian (E22K), and
Iowa (D23N) variants were readily degraded by rIDE
with a similar efficiency. However, proteolysis of A
Dutch (E22Q) and Arctic (E22G) was significantly lower
as compared with A wild type and the rest of the mu-
tant peptides. In the case of A Dutch, inefficient prote-
olysis was related to a high content of  structure as
assessed by circular dichroism. All of the A variants
were cleaved at Glu3-Phe4 and Phe4-Arg5 in addition to
the previously described major sites within positions
13–15 and 18–21. SDS-stable A dimers were highly re-
sistant to proteolysis by rIDE regardless of the variant,
suggesting that IDE recognizes a conformation that is
available for interaction only in monomeric A. These
results raise the possibility that upregulation of IDE
may promote the clearance of soluble A in hereditary
forms of A diseases.
The accumulation of amyloid  peptide (A)1 in the brain is
a central process in a number of human neurodegenerative
disorders that may be grouped as “amyloid  diseases” (1). In
Alzheimer’s disease, A is mainly found within senile plaques
in the neurophil and vascular lesions, whereas in sporadic and
hereditary amyloid angiopathies, A deposits are mainly asso-
ciated with cortical and leptomeningeal vessels leading to
stroke or multi-infarct dementia. To a lesser extent, cerebral
A deposits are also present in normal aging (2). Autosomal
dominant mutations in the amyloid  precursor protein (A
PP) gene result in amino acid substitutions at position 21, 22,
or 23 of A sequence. Although these A variants present with
a primarily vascular deposition, they translate into different
clinical phenotypes. In this regard, A Arctic (E22G) and A
Iowa (D23N) are characterized by presenile dementia and A
Flemish (A21G) is associated with early onset dementia and
cerebral hemorrhage, whereas ADutch (E22Q) and A Italian
(E22K) variants have a predominant vascular phenotype char-
acterized by massive strokes (3–7). The underlying mechanism
of aggregation and deposition in vivo may be strongly influ-
enced by the type of amino acid substitution as well as the
location of mutations in the A peptide. In vitro studies have
shown that A E22Q and A D23N form typical amyloid fibrils
at a higher rate than wild-type A and that A E22G assem-
bles into unique protofibrils that may be toxic to neurons (3,
8–10). In the case of A A21G, overproduction of the peptide
may contribute as a pathogenic mechanism (11, 12). Regarding
A E22K, deposition seems not to be related with fibril forma-
tion rate, and yet this variant may be toxic to human cerebro-
vascular smooth muscle cells in culture (6, 13). In addition to
the intrinsic aggregation properties of A and its genetic vari-
ants or the rate of their production, recent studies (14, 15) in
animal models have suggested that a defective clearance may
influence the progressive accumulation of A in the neurophil
and cerebral vessels. Among the mechanisms that remove A
peptides from the brain, degradation by several proteases in-
cluding neprilysin, endothelin-converting enzyme, and insulin
degrading enzyme (IDE) is now being considered as an impor-
tant component of the A clearance process (16, 17, reviewed in
Refs. 18 and 19). IDE is a highly conserved thiol metallopro-
tease with ubiquitous expression including the brain (20–22).
Regarding its physiological role, IDE has been implicated in
cellular growth and differentiation, modulation of proteasomal
activity, and steroid signaling (23, reviewed in Ref. 24). In
addition to insulin for which the protease has a Km in the low
nanomolar range, IDE is known to degrade several peptides
capable of forming amyloid fibrils in vitro and in vivo including
glucagon, amylin, atrial natriuretic peptide, calcitonin, and A
(25, 26, reviewed in Ref. 27). Studies using rat and human
brain tissue homogenates, IDE-transfected cell lines, and pri-
mary neuronal cultures have supported a role of IDE in A
degradation in vivo (28–31). Moreover, IDE has been shown to
* This work was supported in part by Beca Carrillo On˜ativia, Minis-
terio de Salud (to E. M. C. and L. M.), Agencia Nacional de Promocio´n
Cientı´fica y Tecnologica Grant PICT98-05-04394 (to L. M. and
E. M. C.), Fulbright Scholar Program fellowship (to L. M.), Interna-
tional Society for Neurochemistry-Committee for Aid and Education in
Neurochemistry Award (to E. M. C.), and National Institutes of Health
Grants AG10491, AG08721, and NS38777. The costs of publication of
this article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
 To whom correspondence should be addressed: IQUIFIB,
CONICET, Ca´tedra de Quı´mica Biolo´gica Patolo´gica, Departamento de
Quı´mica Biolo´gica, Facultad de Farmacia y Bioquı´mica, Universidad de
Buenos Aires, Junin 956, C1113AAD, Buenos Aires, Argentina. Tel.:
54-11-4-964-8288; Fax: 54-11-4-962-5457; E-mail: edcast@ffyb.uba.ar.
1 The abbreviations used are: A, amyloid ; A PP, amyloid  pre-
cursor protein; IDE, insulin-degrading enzyme; rIDE, recombinant in-
sulin-degrading enzyme; Tricine, N-[2-hydroxy-1,1-bis(hydroxymeth-
yl)ethyl]glycine; WT, wild type; GST, glutathione S-transferase; CD,
circular dichroism; MALDI-TOF MS, matrix-assisted laser desorption
ionization time-of-flight mass spectrometry; HCHWA-D, hereditary ce-
rebral hemorrhage with amyloidosis, Dutch type.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 278, No. 26, Issue of June 27, pp. 23221–23226, 2003
© 2003 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 23221
 by guest, on Novem
ber 6, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
protect cultured neurons from A toxicity, indicating that the
A fragments generated by IDE are not themselves toxic to
cells (32). Regarding the state of A oligomerization and IDE
specificity, it has been proposed that IDE is able to degrade
efficiently monomeric A as opposed to oligomeric A species
that are thought to be more toxic to neurons or vascular cells
than typical amyloid fibrils (33). However, whether IDE is
capable of degrading A bearing pathogenic amino acid substi-
tutions and how these changes may affect specificity is not
known. The aim of our work was to study the degradation of A
genetic variants associated with human disease by recombi-
nant IDE in vitro and to characterize the proteolytic products
from each of these A mutant peptides.
EXPERIMENTAL PROCEDURES
Expression and Purification of Recombinant Rat IDE—The plasmid
pECE-IDE (kindly provided by Richard Roth, Stanford University),
containing the coding region of rat IDE cDNA was used as a template
for the PCR amplification of a truncated version of IDE using sense
5-AGCACAGGATCCATGAATAATCCGGCCAT-3 (nucleotides 139–
155) and antisense 5-TTCTCGAGGAGTTTTGCCGCCATGA-3 (nucle-
otides 3072–3056) primers of the rat IDE cDNA sequence. Sites for the
restriction enzymes BamHI and XhoI, respectively, were introduced to
facilitate cloning. The PCR DNA fragment was digested with BamHI
and XhoI and cloned into pET-30a() (Novagen) previously digested
with the same restriction enzymes to generate the pET-IDE construct.
Recombinant IDE 42-1019 (rIDE) was expressed in Escherichia coli
BL21 and purified to homogeneity using a Hi Trap Ni-chelating columm
(Amersham Biosciences) following the method described by Chesneau
and Rosner (34). Purity, as assessed by SDS-PAGE, was 95%. rIDE
proteolytic activity was determined using [125I]insulin as described
below.
Production of Anti-IDE Polyclonal Antibodies—A region between
amino acids 97 and 273 of the rat IDE sequence was amplified by PCR
using as template pECE-IDE with the following primers: forward 5-
CTGAGCGGATCCCTGTCAGACCCTCCA-3 and reverse 5-CAATGT-
GAATTCCTTCACCACCAGATT-3. After digestion with BamHI and
EcoRI, the 530-bp insert was subcloned into pGex2T vector (Amersham
Biosciences). GST-IDE97–273 fusion protein was expressed and puri-
fied according to the manufacturer’s suggestions. After immunization of
New Zealand rabbits with GST-IDE97–273, the antiserum (BC2) was
sequentially purified using a BL21/GST lysate coupled to CNBr-acti-
vated Sepharose (Amersham Biosciences) and a GST-agarose (Sigma)
affinity columns, respectively. Specificity of anti-IDE antiserum BC2
was tested by Western blot against GST, GST-IDE97–273, purified
rIDE (see above), and soluble fractions from human and rat brain and
liver in which a single 115-kDa band was detected (data not shown).
Synthetic Peptides—Synthetic A-(1–40)-peptides such as A WT,
A A21G, A E22Q, A E22K, A E22G, A D23N, and A-(1–40)/A-
(1–42) containing the rodent sequence (35) were synthesized by the
W. M. Keck Foundation (Yale University, CT). All of the peptides were
purified by reverse-phase high pressure liquid chromatography, and
their purity was evaluated by amino acid sequence analysis and laser
desorption mass spectrometry. Lyophilized aliquots of the peptides
were dissolved at a concentration of 70 M in distilled water as deter-
mined with a bicinchoninic acid assay (Pierce) after centrifugation at
10,000 rpm for 15 min to eliminate large aggregates. The supernatant
was aliquoted and stored at 80 °C.
SDS-PAGE and Western Blot—Proteins obtained from E. coli BL21
lysates and after the different steps of purification were analyzed by
7.5% SDS-PAGE in Tris-Tricine gels. A peptides were run on 12.5%
Tris-Tricine SDS-PAGE. For Western blot analysis, proteins were
transferred onto nitrocellulose membranes (Hybond ECL, Amersham
Biosciences) and incubated with anti-A monoclonal antibody 6E10
(Signet Laboratories) at 1:1000, anti-IDE monoclonal 9B12 (kindly pro-
vided by Richard Roth) at 1:1000, and polyclonal antibody BC2 at
1:1000. Immunoreactivity was detected with anti-mouse or anti-rabbit
horseradish peroxidase-labeled IgG and ECL Plus (Amersham Bio-
sciences). Immunoblots were scanned with STORM 840 and analyzed
with ImageQuant 5.1 software (Amersham Biosciences).
In-gel Tryptic Digestion of rIDE and Amino Acid Sequencing—After
SDS-PAGE and Coomassie Blue staining, the band of 125 kDa was cut
and the gel slice was incubated in 100 mM ammonium bicarbonate, pH
8.3 containing 45 mM dithiothreitol for 30 min at 60 °C. The tube was
cooled at room temperature, and 100 mM iodoacetamide was added
FIG. 1. Characterization of recombinant rat IDE. Panel A, SDS-
PAGE and Coomassie Blue staining (lanes 1–4) of proteins obtained
during the purification procedure of rIDE. Lane 1, total bacterial lysate;
lane 2, proteins unbound to Ni columm; lane 3, eluate with 100 mM
imidazole; lane 4, eluate with 400 mM imidazole; lane 5, Western blot of
purified rIDE using BC2 polyclonal antiserum. Left, molecular mass
markers in kilodaltons. Panel B, SDS-PAGE and PhosphorImager anal-
ysis of [125I]insulin degradation by rIDE in the presence or absence of
different inhibitors as indicated. Unlabeled insulin was used at 1 M.
Leu, leupeptin; Pep, pepstatin; Phen, 1,10-phenantroline.
FIG. 2. Degradation of A variants by rIDE. Panel A, Western
blot analysis with monoclonal 6E10 of degradation of A WT and A
genetic variants by rIDE. m, A monomers; d, A dimers. Panel B,
densitometric quantitation of the immunoreactivity of A as in panel A.
m, monomers; d, dimers. Bars represent the mean  S.E. of three
independent experiments. *, p  0.01 (Student’s t test) as compared
with A WT.
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followed by incubation for 30 min in the dark at room temperature. The
gel was then washed in 50% acetonitrile, 100 mM ammonium bicarbon-
ate with shaking for 1 h, cut in pieces, and transferred to a small tube.
Acetonitrile was added to shrink the gel pieces, and the sample was
dried in a rotatory evaporator. The gel pieces were re-swollen with 10 l
of 100 mM ammonium bicarbonate, pH 8.3, containing trypsin at a 10:1
ratio (w/w, substrate:enzyme). The sample was incubated overnight at
37 °C, and digestion products were extracted twice from the gel with
60% acetonitrile, 0.1% trifluoroacetic acid for 20 min. Combined extrac-
tions were loaded into a C18 high pressure liquid chromatography
column (220  1 mm), and peptides eluted with a linear gradient from
0 to 100% acetonitrile, 0.1% trifluoroacetic acid. Selected peaks were
applied to a 477A protein-peptide sequencer (Applied Biosystems) and
subjected to Edman degradation sequence analysis at the Laboratorio
Nacional de Investigacı´on y Servicios en Pe´ptidos y Proteinas facility
(CONICET).
Degradation Assays—1 g of each A synthetic peptide was incu-
bated alone or with 500 ng of purified rIDE in 10 l of 100 mM sodium
phosphate buffer, pH 7, in the presence or absence of 1 mM 1,10-
phenantroline. After 30, 60, 90, and 120 min of incubation at 37 °C,
samples were analyzed by SDS-PAGE and Western blot with 6E10 as
described above. After each time point, degradation by rIDE was ex-
pressed as the percentage of remaining A monomer or dimer as com-
pared with A incubated without the enzyme. [125I]Insulin (specific
activity 300 Ci/g, kindly provided by Edgardo Poskus, University of
Buenos Aires.) was incubated with rIDE alone or in the presence of the
following sets of inhibitors: 1) 1 M unlabeled insulin; 2) a mixture of 2
mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, and 10 g/ml
pepstatin A; 3) a mixture of 1 mM 1,10-phenantroline and 5 mM EDTA,
respectively, in the same buffer as above. After incubation for various
time points, the sample was run on SDS-PAGE, and the remaining
intact [125 I]insulin was analyzed and quantitated with a STORM 840
PhophorImager (Amersham Biosciences).
Circular Dichroism (CD) Spectra—Aliquots of A synthetic peptides
freshly dissolved at 60 M in 10 mM Tris-HCl, pH 7.5, were loaded into
a 0.1-nm path length quartz cell, and the circular dichroism spectra
were recorded in the far-ultraviolet light using a JASCO J-720 spec-
tropolarimeter (JASCO Corporation). Forty scans for each experimental
condition were obtained at 0.2-nm intervals over the wavelength range
of 190–260 nm. Final spectra were obtained after the subtraction of
background readings of blanks.
Mass Spectrometry Analysis—Molecular masses of intact A pep-
tides and the products of rIDE degradation were determined at the New
York University Protein Analysis Facility. A-containing samples (10
l of final volume) were passed through reversed-phase ZipTip (Milli-
pore) following manufacturer’s instructions and analyzed on a Micro-
mass TofSpec-2E (MALDI-TOF) mass spectrometer in linear mode us-
ing standard instrument settings. Internal and/or external calibration
TABLE I
Mass spectrometry analysis of the cleavage products of A variants by insulin-degrading enzyme
NF, not found; Obs., observed; Calc., calculated.
A
fragment
Molecular mass of A variants
AWT AA21G AE22K AE22Q AE22G AD23N Arodent
Obs. Calc. Obs. Calc. Obs. Calc. Obs. Calc. Obs. Calc. Obs. Calc. Obs. Calc.
Da
1–13 1561.8 1561.6 NF 1562.6 1561.6 1561.9 1561.3 1562.2 1561.6 1562.1 1561.6 1466.3 1465.5
1–14 1699 1698.3 1699.5 1693.7 1699.9 1698.7 1699.5 1698.7 1699.4 1698.7 1699.3 1698.7 1603.7 1602.6
1–18 2167.9 2167.3 NF 2165.6 2167.3 NF 2168.9 2167.3 2168.1 2167.3 2072.9 2071.2
1–19 2315.1 2314.5 2315.6 2314.5 NF NF 2315.7 2314.5 2315.3 2314.5 2220.2 2218.4
1–20 2462.6 2461.7 NF 2462.9 2461.7 NF NF NF NF
1–26 NF NF NF NF NF 3019.2 3019.2 NF
1–28 NF NF NF NF NF 3261.3 3261.5 3168.2 3166.5
4–13 1246.4 1246.3 1246.8 1246.3 1247 1246.3 1246.7 1246.3 1246.7 1246.3 1246.7 1246.3 1151.2 1150.2
4–14 1383.7 1383.5 1384 1383.5 1384.2 1385.5 1384 1383.4 1384 1383.5 1383.9 1385.5 NF
4–19 2000 1999.2 NF NF NF NF NF NF
5–14 1236.3 1236.3 1236.8 1236.3 1237 1236.3 1236.6 1236.3 1236.6 1236.3 1236.6 1236.3 NF
14–20 NF NF NF 918.9 918.1 NF NF NF
14–28 1719.4 1718.9 1705.8 1704.9 NF NF 1647.4 1646.9 NF NF
15–26 NF NF NF NF NF 1338.6 1338.5 NF
15–28 1582 1581.8 1568.3 1567.8 NF NF 1510.5 1509.7 NF NF
15–40 NF NF 2650.5 2648.2 NF 2578.5 2579.1 NF NF
19–28 NF 1100.2 1099.2 NF NF NF NF NF NF
19–40 2180.4 2180.6 NF NF NF NF NF NF
20–40 NF 2020.3 2019.4 2033.5 2032.4 2033.8 2032.4 1962.1 1961.3 2033.1 2032.3 2034.6 2033.5
21–40 NF NF 1886.6 1885.3 1886.5 1885.2 1814.6 1814.1 1885.7 1885.2 1887.5 1886.2
27–40 NF NF NF NF NF 1327.7 1327.7 NF
29–40 NF 1084.9 1085.4 NF NF 1085.5 1086 NF NF
FIG. 3. Schematic representation of cleavage sites within A
WT, A rodent, and A human genetic variants by rIDE. Arrows
show the peptide bonds hydrolyzed by rIDE. Open arrowheads (ƒ)
indicate loss of cleavage under the experimental conditions tested. The
lines represent identity of amino acid sequence and cleavage sites.
Amino acid substitutions in each A variant are shown in circles.
FIG. 4. Circular dichroism spectra of A variants. Aliquots (400
g) of each peptide were dissolved in 1.5 ml of 10 mM Tris-HCl buffer,
pH 7.5. After centrifugation at 14,000 rpm for 5 min to remove aggre-
gates, CD spectra were recorded in a JASCO spectropolarimeter J-720
in a 0.1-cm path length cell. Results are expressed as mean residue
ellipticity in units of deg cm2 dmol1 after substraction of buffer spectra
and smoothing with algorithm provided by JASCO. Spectra: 1, A
E22G; 2, A WT; 3, A D23N; 4, A A21G; 5, A E22K and 6, A E22Q.
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was carried out using angiotensin I (average mass  1296.5 Da) and
insulin (average mass  5733.5 Da).
Isolation of A from Leptomeningeal Vessels—Leptomeningeal vas-
cular amyloid from a patient with hereditary cerebral hemorrhage with
amyloidosis Dutch type (HCHWA-D) was isolated as described previ-
ously (36). Leptomeninges were dissected from brain coronal sections,
cut with scissors into 1–3-mm pieces, and placed in 0.1 M Tris-HCl, pH
8, on ice. Tissue was then washed by resuspension in 0.1 M Tris-HCl, pH
8, containing protease inhibitors (buffer A) and centrifuged at 800  g
for 5 min at 4 °C. The procedure was repeated 5 times. The material
was collected by filtration through a 50-m nylon mesh (Spectrum),
washed with buffer A without inhibitors, and resuspended in 20 vol-
umes of 2 mM CaCl2 in 0.1 M Tris-HCl, pH 7.5, containing 0.3 mg/ml
collagenase CLS-3 (Worthington) and 10 g/ml DNase (Worthington).
The mixture was incubated for 18 h at 37 °C. After digestion, the
suspension was filtered through a 350-m nylon mesh and the filtrate
was centrifuged at 10,000  g for 12 min. The pellet was resuspended
in 2% SDS in 0.1 M Tris-HCl, pH 8, and incubated for 2 h at room
temperature. The SDS-insoluble material was recovered by centrifuga-
tion as above and washed three times with distilled water. The pellet
was dissolved in 10 volumes of 99% formic acid (Sigma) and incubated
for 1 h at room temperature. After centrifugation at 10,000  g for 10
min, the supernatant was then loaded on a Superose 12 column (10 
300 mm) (Amersham Biosciences). Amyloid peptides were separated in
75% formic acid at 0.2 ml/min using a Bio-Cad Sprint chromatography
system. Eluent was monitored at 280 nm, collected in 1-ml fractions,
and analyzed as above.
RESULTS
Expression and Characterization of Recombinant Rat IDE—
Our IDE bacterial expression vector pET-IDE encodes rat IDE
(positions 42–1019) with a His6 tag at its N terminus to facil-
itate the purification of the protease with a Ni-affinity columm.
After elution with a step gradient of increasing imidazole con-
centrations, we obtained a highly purified recombinant protein
with an apparent molecular mass of 125 kDa as assessed by
SDS-PAGE. Western blot using our polyclonal antibody BC2
specifically recognized this 125-kDa fusion protein (Fig. 1A).
Unexpectedly, the protein did not display immunoreactivity on
Western blot with monoclonal 9B12, a well characterized anti-
rat IDE antibody (data not shown) (37). To determine its iden-
tity, we performed “in-gel” digestion with trypsin followed by
separation on microbore high pressure liquid chromatography
and N-terminal amino acid sequence of a tryptic fragment. The
sequence NVPLPEF matched positions 282–288 of rat IDE
(20), confirming the identity of our recombinant protease and
suggesting that 9B12 may indeed recognize a posttranslation-
ally modified epitope in rat IDE that is not present in IDE
expressed in bacteria. To characterize the activity of recombi-
nant rIDE, we analyzed the degradation of [125I]insulin. After
1 h of incubation, rIDE was able to digest [125I]insulin and this
activity was totally inhibited by EDTA-1,10-phenantroline and
blocked to 80% in the presence of 1 M unlabeled insulin (Fig.
1B). These results are fully consistent with the reported char-
acterization of human recombinant IDE expressed in E. coli
(34) and rat recombinant IDE produced in a baculovirus-insect
cell system (32).
Degradation of A WT and A Genetic Variants by rIDE—We
followed the degradation of A WT and A genetic variants by
rIDE using SDS-PAGE and Western blot with monoclonal 6E10
that recognizes an epitope within positions 1–16 of A (38) The
relative amount of A monomers and dimers that remained intact
after incubation with rIDE was estimated by densitometry. This
method allowed an accurate discrimination between monomeric
and oligomeric A as opposed to high pressure liquid chromatog-
raphy or trichloroacetic acid precipitation (28, 29). The absence of
A degradation products on Western blots may reflect the loss of
the 6E10 epitope attributed to rIDE activity. Alternatively, the A
N-terminal fragments generated by the protease may be too small
to be detected on SDS-PAGE. Under the conditions of our assay,
the quantitation of degradation showed linearity up to 90 min of
incubation (data not shown); therefore, a 60-min incubation was
the time selected for the comparative analysis. As indicated in Fig.
2, A and B, monomeric A WT, A A21G, A E22K, and A D23N
were degraded at 75.2 3, 81.5 9.2, 79.5 12, and 84.7 7.6%,
respectively. rIDE was substantially less efficient in degrading A
E22Q and A E22G monomers (42.3  6 and 34.6  6%, respec-
tively, p  0.01 as compared with A WT). In the presence of
1,10-phenantroline, degradation of A WT was inhibited almost
completely (Fig. 2B). In contrast to A monomers, degradation of
FIG. 5. Degradation of A E22Q from HCHWA-D leptomeningeal vessels by rIDE. MALDI-TOF MS analysis of native A E22Q extracted
in formic acid after incubation for 1 h at 37 °C in the absence (panel A) or in the presence (panel B) of rIDE. St, standard (insulin mass/2H). Insets,
calculated and observed masses of A E22Q species and predicted peptides. The presence of one or two formic acid molecules is indicated by F or
2F, respectively. Ox, oxidized. Panel C, Western blot analysis with monoclonal 6E10 after incubation of A E22Q from HCHWA-D leptomeningeal
vessels with rIDE. Synthetic A E22Q (lane 1) and HCHWA-D amyloid incubated for 1 h at 37 °C alone (lane 2) and with rIDE (lane 3) are shown.
Left, molecular masses in kilodaltons.
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dimers was consistently 10% for all of the variants studied (Fig.
2B), in agreement with the results reported recently on endogenous
A WT generated by A PP-transfected cell lines (33).
Characterization of A Proteolytic Products—A WT proteo-
lytic products generated by rIDE were consistent with previous
reports with the major sites of cleavage at His13-His14, His14-
Gln15, Val18-Phe19, Phe19-Phe20, Phe20-Ala21, and Lys28-Gly29
(28, 32, 39). All of the A fragments observed by MALDI-TOF
MS are summarized in Table I, and Fig. 3 shows an schematic
representation of the cleavage sites. Several fragments starting
at Phe4 and Arg5 were found in A WT and in all of the A
variants. These peptides were not the products of truncated
synthesis as shown by MS analysis of undigested A peptides
and were not found when As were incubated with rIDE in the
presence of 1,10-phenantroline (data not shown). Moreover,
Phe and Arg as P1 residues are compatible with the known
specificity of IDE (28, 41). Therefore, it seemed probable that
rIDE was capable of hydrolyzing A Glu3-Phe4 and Phe4-Arg5
peptide bonds. In A A21G, there was a consistent absence of
fragments ending at Phe20 or starting at Gly21, suggesting the
specific loss of a cleavage site. Notably, when we analyzed the
digestion of rodent A that present Gly instead of Arg at
position 5, no fragments indicative of hydrolysis at the Phe4-
Gly5 site were found, neither in rodent A-(1–40) (Table I and
Fig. 3) nor in rodent A-(1–42) (data not shown), whereas all of
the other cleavage sites present in human A WT were con-
served. The Dutch variant A E22Q showed the apparent loss
of sites at Val18-Phe19 and Lys28-Gly29, whereas in the Italian
variant A E22K, the latter cleavage site was also absent. This
peptide bond has been reported to be resistant to IDE in A
WT-(1–42) (32), and therefore, its hydrolysis by IDE may de-
pend upon oligomerization rather than primary structure. Al-
ternatively, the presence of Gly at P1 may impose a subsite
restriction as suggested by the loss of cleavage sites in the A
Flemish and rodent variants. The Iowa type A D23N differed
notably from all of the other A peptides studied. Fragments
consistent with positions 1–26, 15–26, and 27–40 were found,
indicating the cleavage at the Ser26-Asn27 bond (Table I and
Fig. 3) and pointing to the possible importance of the Asp23 in
the folding of the A peptide.
Effect of A Secondary Structure upon Degradation by
rIDE—To study the possible influence of secondary structure of
A variants on the susceptibility to degradation by rIDE, we
performed CD analysis of all of the peptides freshly dissolved in
aqueous buffer at neutral pH without previous incubation and
after the removal of large aggregates by centrifugation. As
expected, A E22Q displayed a negative peak at 220 nm and a
positive peak at 195 nm consistent with a  structure in solu-
tion (6). In contrast, A WT, A A21G, A E22G, A E22K, and
A D23N showed a strong negative peak at 198 nm correspond-
ing to unordered structures (Fig. 4).
Degradation of A E22Q Purified from Leptomeningeal Ves-
sels by riDE—To determine whether rIDE was capable of de-
grading the Dutch A variant present in affected human tis-
sue, we used purified A from leptomeningeal vessels from a
case of HCHWA-D that was extensively characterized previ-
ously (36). After the removal of formic acid by reverse-phase
C18 Zip Tip and equilibration of the sample at neutral pH, A
Dutch was incubated with rIDE and degradation characterized
as above. Western blot showed that A Dutch was extensively
aggregated into SDS-resistant oligomers of 	22–25 kDa that
were unmodified in the presence of rIDE (Fig. 5C). However,
MALDI-TOF MS analysis revealed the disappearance of mono-
meric A Dutch and the generation of two fragments, positions
1–19 and 1–20 (Fig. 5, A and B), that were not seen in the
presence of 1,10-phenantroline (data not shown).
DISCUSSION
Our results demonstrated that rIDE was capable of degrad-
ing all of the synthetic A variants associated with human
disease and A Dutch purified from leptomeningeal vessels.
However, the efficiency of degradation of synthetic A mono-
meric species by rIDE was significantly lower for A E22Q and
A E22G as compared with A WT and the rest of the variant
A peptides studied. The concentrations of A peptides used in
our assays were above the critical concentration of A-(1–40)
for the formation of high molecular weight oligomers (41), and
therefore, it is likely that aggregation of A strongly influenced
the rate of degradation by rIDE. In the case of the A Dutch
variant, a possible slower rate of degradation could be ex-
plained by the high content of  structure as shown by CD
analysis. This result was fully consistent with several in vitro
studies that have demonstrated the fast rate of assembly into
stable fibrils of this A mutant (8, 9, 36). The early deposition
of A E22Q and onset of symptoms in HCHWA-D patients
strongly suggest that such mechanism may be relevant in vivo.
Moreover, the amyloidogenic conformation of A E22Q may be
dominant because A WT has been also found in the
HCHWA-D vascular deposits (42). The A Arctic variant pep-
tide in turn has been shown to self-assemble rapidly into pro-
tofibrils that may be toxic to neural cells (3). Although the
major quantitative differences in degradation were seen upon
A E22Q and A E22G, it is unlikely that they reflect a pro-
tease-resistant conformation of these monomeric A species.
The models based on NMR have shown a similar coiled flexible
structure in aqueous solution for A E22Q and A WT (43, 44).
Moreover, we have previously demonstrated that at physiolog-
ical concentrations in the low nanomolar range, A WT and A
E22Q were degraded at a similar rate by endogenous brain IDE
(29). Thus, it seems more likely that monomeric A Dutch and
Arctic variants were “hidden” from rIDE into higher oligomers
or aggregates during incubation in physiological buffer that
were then partially dissociated upon SDS treatment for West-
ern blot analysis. It was notorious that all of the SDS-resistant
A dimers including those from A WT were poorly degraded
by rIDE, consistent with the resistance to proteolysis of native
A WT-soluble oligomers in cultured cells overexpressing A
PP (33). However, it cannot be concluded from these experi-
ments whether A dimers or higher oligomers are the resistant
species to degradation by rIDE. The separation of stable A
oligomers by gel filtration under native conditions is needed to
clarify this issue. In any case, our results and previous reports
(28, 48) support that IDE recognizes a motif on monomeric A
within positions 18–22, a known hydrophobic stretch that is
critical for amyloid formation (45–47). It may be possible that
when these residues participate in peptide self-assembly, they
are no longer accessible to IDE catalytic site. Our findings on
A D23N showed an apparent discrepancy with those pre-
sented recently by Van Nostrand et al. (10). In these reported
experiments, A Iowa and A Dutch variants behaved simi-
larly in terms of secondary structure and fibrillization rate
after 48 h of incubation. Nevertheless, it is possible that at
much shorter times of incubation, such as in our degradation
and CD experiments, the rate of assembly into a  structure
may be substantially faster for A E22Q as compared with A
D23N, resulting in a higher resistance to proteolysis by rIDE.
The A Iowa peptide was different among all of the A vari-
ants, because it presented a unique site of cleavage by rIDE at
Ser26-Asn27. The possibility of multiple subsite interactions
allowing different alignments of substrate relative to the site of
catalysis in IDE has been recently demonstrated with the use
of fluorogenic substrates (40). It remains to be addressed
whether Asn instead of Asp at position 23 of A, being at P4
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from Ser26-Asn27, may determine a new site of cleavage that
seems atypical in light of the preference of IDE for hydrophobic
and basic residues at P1 (27, 40). In addition to overproduction
and an enhanced aggregability imposed by amino acid substi-
tutions, A may accumulate in the brain due to defective clear-
ance. In transgenic mice expressing human A PP with path-
ogenic mutations that promote the activity of -secretase such
as the double K670N/M671L substitution, the time course of
amyloid deposition shows an exponential increase after 9–10
months of age (15, 49). Yet, the rate of A production and
-secretase activity seems to remain constant throughout the
life span of these mice (14). A defect in reverse transport to the
systemic circulation as shown for the A Dutch variant (50, 51)
together with inefficient local proteolysis may determine a rise
in the levels of A in the brain and therefore accelerate its rate
of aggregation and deposition (16, 29, 52). In the case of human
diseases associated with mutations clustered within the middle
portion of A, such accumulation shows a remarkable predis-
position for vessels in which A oligomers may be toxic to
endothelial and smooth muscle cells. Our results in vitro raise
the possibility that upregulation of IDE may promote the clear-
ance of these A genetic variants in vivo. In this regard, it is
noteworthy that A pathogenic mutants seem to be highly
resistant to proteolysis by neprilysin in vitro, and therefore,
increasing the activity of neprilysin may be inefficient to pre-
vent A deposition in certain hereditary forms of amyloid 
diseases (53). Yet, the apparent resistance of A oligomers to
proteolysis by rIDE suggests that any strategy to lower A
based on the enhancement of this endogenous protease should
aim at the degradation of A at its monomeric state.
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